Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models Publication Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…CertaraMay 21, 2026
Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned On-Demand Webinar Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned Learn how Phoenix NLME and RsNLME support advanced PK/PD workflows and complex pharmacometric modeling through…CertaraMay 20, 2026
Minimize risk when preparing for hepatic impairment studies Webinar Minimize risk when preparing for hepatic impairment studies CertaraMay 12, 2026
Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace On-Demand Webinar Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace See how Phoenix NLME and RsNLME support scalable and manageable workflows as project demands evolve.Danielle PillsburyMay 8, 2026
BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs Webinar BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs CertaraMay 8, 2026
What We Learned at Phoenix UGM at Certainty 2026 About the Future of PK/PD Blog What We Learned at Phoenix UGM at Certainty 2026 About the Future of PK/PD JTVCdGVhbV9qdW1wX2xpc3QlNUQ= May 8, 2026 At Certainty 2026, the Phoenix User Group Meeting brought together scientists,…CertaraMay 8, 2026
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome Publication Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…CertaraMay 7, 2026
Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Publication Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…CertaraMay 7, 2026
Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies Publication Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…CertaraMay 7, 2026
Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint On-Demand Webinar Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint Explore how Phoenix NLME and RsNLME support early phase clinical pharmacology workflows where speed, clarity,…CertaraMay 6, 2026